This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Boehringer Ingelheim GmbH

Drug Names(s): FX125L

Description: FX125L is an orally available, once-daily small molecule which belongs to the class of somatotaxins.

Deal Structure: Boehringer Ingelheim and Funxional
Boehringer Ingelheim and Funxional Therapeutics announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics FX125L compound and somatotaxin programme.

Boehringer Ingelheim will be responsible for all further research, development and commercialization of FX125L. Financial details of the transaction were not disclosed.

Partners: Funxional Therapeutics Ltd

FX125L News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug